WO2019188943A1 - Composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral - Google Patents

Composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral Download PDF

Info

Publication number
WO2019188943A1
WO2019188943A1 PCT/JP2019/012421 JP2019012421W WO2019188943A1 WO 2019188943 A1 WO2019188943 A1 WO 2019188943A1 JP 2019012421 W JP2019012421 W JP 2019012421W WO 2019188943 A1 WO2019188943 A1 WO 2019188943A1
Authority
WO
WIPO (PCT)
Prior art keywords
bifidobacterium
composition
blood flow
present technology
preventing
Prior art date
Application number
PCT/JP2019/012421
Other languages
English (en)
Japanese (ja)
Inventor
葉月 前畑
洋大 小林
徹哉 久原
Original Assignee
森永乳業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 森永乳業株式会社 filed Critical 森永乳業株式会社
Priority to JP2020510056A priority Critical patent/JPWO2019188943A1/ja
Publication of WO2019188943A1 publication Critical patent/WO2019188943A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • Cerebrovascular dementia is the most common dementia after Alzheimer's dementia. However, research and development of compounds for preventing or ameliorating Alzheimer-type dementia are being actively carried out, whereas research and development of compounds for preventing or ameliorating cerebrovascular dementia are still insufficient.
  • a method for producing a food / beverage product composition for preventing / ameliorating cerebrovascular dementia comprising the following steps (A) to (B): (A) culturing Bifidobacterium in a medium, (B) A step of subjecting the culture to freeze-drying to obtain a bacterial powder.
  • One or more selected from the group consisting of these can be used.
  • the form of the genus Bifidobacterium is not particularly limited, and may be any form such as live cells, dead cells, sterilized cells, wet bacteria, dried bacteria, and crushed materials thereof. Of these forms, a wet or dry state is not considered, but live cells and / or dead cells are preferable, and live cells are more preferable.
  • Bifidobacterium longum NITE BP-02621 (Bifidobacterium longum BB536) is an independent administrative agency, National Institute for Product Evaluation Technology, Patent Microorganism Depositary Center (NPMD) No. 2-5-8 Room 122) was deposited on January 26, 2018 under the deposit number of NITE BP-02621 under the Budapest Treaty.
  • Longum ATCC BAA-999 (number: ATCC BAA-999), which is the same bacterium, is available as ATCC BAA-999 from the American Type Culture Collection (ATCC) (for example, JP 2012-223134 etc.).
  • the medium for culturing the Bifidobacterium is not particularly limited, and a medium usually used for culturing the Bifidobacterium can be appropriately modified as necessary.
  • a medium usually used for culturing the Bifidobacterium can be appropriately modified as necessary.
  • the carbon source of the medium for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and molasses can be used depending on utilization.
  • ammonium salts such as ammonia, ammonium sulfate, ammonium chloride, and ammonium nitrate, and nitrates can be used.
  • Non-therapeutic purpose is a concept that does not include medical practice, that is, treatment of the human body by treatment. For example, health promotion, lifestyle-related disease prevention (for example, a reserve army in a border region), and the like.
  • Prevention refers to prevention or delay of the onset of a disease or symptom in the application subject, or a reduction in the risk of the disease or symptom to be applied.
  • “Improvement” refers to improvement of a disease, symptom or condition; prevention or delay of exacerbation; reversal, prevention or delay of progression.
  • the milk component is not particularly limited, for example, milk, buffalo milk, sheep milk, goat milk, horse milk, skim milk, skim concentrated milk, skim milk powder, concentrated milk, whole milk powder, cream, butter, butter milk, Condensed milk, milk protein, etc. can be mentioned, 1 type, or 2 or more types chosen from the group which consists of these can be used.
  • milk protein for example, a whey, casein, these hydrolysates, etc. are mentioned, 1 type, or 2 or more types chosen from the group which consists of these can be used.
  • milk components those derived from milk are preferred.
  • the form of the genus Bifidobacterium or a culture containing the same is not particularly limited and may be either liquid or solid, but the form may be in a dry form (for example, a fungus or a culture dry product). From the viewpoint of easy handling during production and storage, it is preferable.
  • the culture include the microbial cells themselves from which the culture solution has been separated and the culture containing the microbial cells as described above.
  • Example 2 of the production method of the present technology is a method of producing a milk beverage or dairy product containing the Bifidobacterium bacterium of the present technology.
  • a step of mixing the bacterial powder obtained in Example 1 of the above-described manufacturing method with milk or skim milk is performed.
  • the bacteria of this technique in the said powder are mix
  • the milk drink or dairy product for uses, such as a cerebral blood-flow fall prevention / improvement, can be provided.
  • the administration target is usually preferably a human, but includes mammals other than humans, for example, pet animals such as dogs and cats, and livestock such as cows, sheep and pigs.
  • the daily dose of Bifidobacterium (live or dead) of the present technology is not particularly limited, but is 1 ⁇ 10 3 to 1 ⁇ 10 12 CFU / day (or cells / cell) / day. 1 ⁇ 10 5 to 1 ⁇ 10 11 CFU / day (or cells (units) / day), more preferably 1 ⁇ 10 7 to 1 ⁇ 10 10 CFU / day (or cells (pieces) / day) is more preferable.
  • components such as excipients, pH adjusters, colorants, flavoring agents and the like that are usually used for formulation can be used in addition to Bifidobacterium bacteria.
  • a component having an effect of preventing or treating a known or future disease can be used in combination according to the purpose.
  • the composition is used for cerebrovascular dementia; or a symptom caused by a decrease in cerebral blood flow or The disease is cerebrovascular dementia; or prevention of one or more symptoms or diseases selected from the group consisting of cerebrovascular dementia, dizziness, dizziness on standing, paralysis of limbs, headache, tinnitus ⁇ It is used for improvement and treatment.
  • the composition is a pharmaceutical composition or a food and beverage composition; or the composition is for non-therapeutic purposes; Alternatively, the use, administration or ingestion of the Bifidobacterium is a non-therapeutic purpose.
  • NITE BP-02621 strain accesion number: NITE BP-02621
  • Contractor Kazusa-Kama, Kisarazu City, Chiba Prefecture, Japan 292-0818 2-5-8, Room 122, National Institute for Product Evaluation Technology Patent Microorganism Depositary Center (NPMD).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral. La composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral contient une bactérie du genre Bifidobacterium en tant que principe actif. De préférence, la bactérie du genre Bifidobacterium est Bifidobacterium longum et/ou Bifidobacterium breve. La composition est également utilisée contre la démence cérébrovasculaire. De préférence, la composition est également une composition médicinale ou une composition alimentaire ou de boisson.
PCT/JP2019/012421 2018-03-26 2019-03-25 Composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral WO2019188943A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020510056A JPWO2019188943A1 (ja) 2018-03-26 2019-03-25 脳血流低下の予防及び／又は改善用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-058805 2018-03-26
JP2018058805 2018-03-26

Publications (1)

Publication Number Publication Date
WO2019188943A1 true WO2019188943A1 (fr) 2019-10-03

Family

ID=68059971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/012421 WO2019188943A1 (fr) 2018-03-26 2019-03-25 Composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral

Country Status (2)

Country Link
JP (1) JPWO2019188943A1 (fr)
WO (1) WO2019188943A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111172074A (zh) * 2020-01-21 2020-05-19 北京科拓恒通生物技术股份有限公司 一株具有缓解改善阿尔茨海默症状的乳双歧杆菌Probio-M8及应用
WO2021145113A1 (fr) * 2020-01-17 2021-07-22 森永乳業株式会社 Composition anti-âge

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519873A (ja) * 2012-03-30 2015-07-16 ネステク ソシエテ アノニム ４−オキソ−２−ペンテン酸及び脳の健康
WO2017130859A1 (fr) * 2016-01-28 2017-08-03 森永乳業株式会社 Inhibiteur de l'apoptose des cellules neuronales
WO2017209156A1 (fr) * 2016-05-31 2017-12-07 森永乳業株式会社 Agent améliorant la fonction cérébrale
WO2018100776A1 (fr) * 2016-11-29 2018-06-07 森永乳業株式会社 Promoteur de la production d'aglycone
US20180271919A1 (en) * 2015-02-03 2018-09-27 Winclove Holding B.V. Probiotic composition at least comprising bifidobacterium bifidum w23 and capable of controlling intestinal barrier function

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519873A (ja) * 2012-03-30 2015-07-16 ネステク ソシエテ アノニム ４−オキソ−２−ペンテン酸及び脳の健康
US20180271919A1 (en) * 2015-02-03 2018-09-27 Winclove Holding B.V. Probiotic composition at least comprising bifidobacterium bifidum w23 and capable of controlling intestinal barrier function
WO2017130859A1 (fr) * 2016-01-28 2017-08-03 森永乳業株式会社 Inhibiteur de l'apoptose des cellules neuronales
WO2017209156A1 (fr) * 2016-05-31 2017-12-07 森永乳業株式会社 Agent améliorant la fonction cérébrale
WO2018100776A1 (fr) * 2016-11-29 2018-06-07 森永乳業株式会社 Promoteur de la production d'aglycone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILBERT, K ET AL.: "Attenuation of post-myocardial infarction depression in rats by n-3 fatty acids or probiotics starting after the onset of reperfusion.", BRITISH JOURNAL OF NUTRITION, vol. 109, no. 1, 2013, pages 50 - 56, XP055638589 *
MAEHATA HAZUKI: "Inhibitory effect of bifidobacterium administration on cognitive decline in cerebrovascular demntia model", DEMENTIA JAPAN, vol. 32, no. 3, pages 440 *
MAEHATA HAZUKI: "Possibility of improvement effect on cognitive function towards mild cognitive impairment by bifidobacterium breve A1 single arm, controlled before-and after trial - lectuure number: 3B07a07", BIFIDOBACTERIUM BREVE A1- PROCEEDINGS OF THE ANNUAL MEETING OF JAPAN SOCIETY FOR BIOSCIENCE BIOTECHNOLOGY AND AGROCHEMISTRY, 5 March 2018 (2018-03-05) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021145113A1 (fr) * 2020-01-17 2021-07-22 森永乳業株式会社 Composition anti-âge
JPWO2021145113A1 (fr) * 2020-01-17 2021-07-22
JP7419404B2 (ja) 2020-01-17 2024-01-22 森永乳業株式会社 抗老化用組成物
CN111172074A (zh) * 2020-01-21 2020-05-19 北京科拓恒通生物技术股份有限公司 一株具有缓解改善阿尔茨海默症状的乳双歧杆菌Probio-M8及应用
CN111172074B (zh) * 2020-01-21 2022-07-29 北京科拓恒通生物技术股份有限公司 一株具有缓解改善阿尔茨海默症状的乳双歧杆菌Probio-M8及应用

Also Published As

Publication number Publication date
JPWO2019188943A1 (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
WO2019117212A1 (fr) Composition contenant une bactérie appartenant au genre bifidobacterium en tant que substance active
CN111935995A (zh) 营养组合物以及使用了该营养组合物的饮食品组合物和配方奶粉
WO2020246585A1 (fr) Composition nutritionnelle
JP7285096B2 (ja) ストレス緩和用組成物並びに該ストレス緩和用組成物を用いた医薬品組成物及び飲食品組成物
US11324784B2 (en) Sleep-promoting composition, and medical composition and food beverage composition using said sleep-promoting composition
WO2017104850A1 (fr) Agent destiné à promouvoir la croissance de de bactéries bifidobacterium et/ou de bactéries lactiques et/ou empêcher la diminution de ces dernières
JP2019116423A (ja) 整腸用組成物
JPWO2020246583A1 (ja) 組成物
WO2019188943A1 (fr) Composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral
US11045508B2 (en) Composition for preventing or improving impaired renal function, pharmaceutical composition, food/beverage composition, and method of preventing or improving impaired renal function using the composition for preventing or improving impaired renal function
JP7368484B2 (ja) 組成物並びに該組成物含有する飲食品組成物および調製乳
JP7475155B2 (ja) 持久力向上用組成物
JP2019167327A (ja) ビフィドバクテリウム属細菌を有効成分とする、ｉｉｉ型インターフェロン産生促進用組成物
WO2021149663A1 (fr) Composition
JP6847577B2 (ja) ビフィドバクテリウム属細菌および／または乳酸菌の増殖促進および／または減少抑制剤
WO2020116511A1 (fr) Composition servant à la suppression d'une infection au norovirus
WO2020251044A1 (fr) Composition ayant pour principe actif une bactérie bifidobacterium
JP7309436B2 (ja) 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
WO2019180965A1 (fr) Composition pour nourrisson destinée à prévenir les maladies provoquées par l'hyperglycémie à partir de l'âge scolaire
WO2019180964A1 (fr) Composition favorisant la sécrétion de fgf21
JP7299744B2 (ja) 血中尿酸値低減用組成物、及び高尿酸血症予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物
JP7516053B2 (ja) 組成物並びに飲食品組成物、栄養組成物および調製乳
JP7333732B2 (ja) 筋肉量及び／又は筋力の維持、或いは筋肉量及び／又は筋力の低下抑制用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物
WO2022064839A1 (fr) Composition destinée à réguler l'expression d'un gène impliqué dans la production ou la dégradation du collagène, de l'élastine ou de l'acide hyaluronique
JP2021042143A (ja) 脂質代謝異常及び／又は糖代謝異常の予防又は改善用組成物、並びに、該組成物を用いた医薬品組成物及び飲食品組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19775552

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020510056

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19775552

Country of ref document: EP

Kind code of ref document: A1